Stämm is a biotechnology company focused on revolutionizing biomanufacturing by making it easy, scalable, and repeatable. Founded with the vision of decentralizing bioproduction, Stämm has developed the first methodology for continuous industrial production of biologics and cell therapies using microfluidics and 3D printing. Their innovative approach mimics nature’s use of laminar flow to condense a full-scale biotech facility into an all-in-one, plug-and-play desktop unit, targeting the biopharmaceutical market.
Notable figures associated with Stämm include its founders and key investors who have supported its mission to innovate biomanufacturing. The company has achieved significant milestones, including the successful development and implementation of its microfluidic and 3D printing technologies. Stämm's impact on the industry is marked by its potential to transform how biologics and cell therapies are produced, making these critical treatments more accessible and cost-effective.
